Admetsys
About Admetsys
Admetsys has developed a first-of-its-kind artificial pancreas for hospital and surgical care, leveraging adaptive learning algorithms and counterbalancing treatment of insulin and glucose.The system has undergone 3 successful FDA-approved clinical trials with 97% control between 80–125 mg/dl and zero incidents of low blood sugar.
YEAR FOUNDED:
2010
LEADERSHIP:
Founders: Timothy Valk, Glenn Robertelli and Jeff Valk
3 articles about Admetsys
-
Admetsys' FDA Breakthrough Designation Accelerates Arrival of Fully Autonomous Clinical Robotics in Hospital
9/6/2023
Admetsys Corporation, a biomedical technology company specializing in critical care automation, announced today that the FDA has designated its automated glucose control and continuous blood diagnostics system a Breakthrough Device.
-
Admetsys Secures CE Mark Approval for PrecisionOne™ Automated Glycemic Control and Continuous Diagnostics System
10/13/2020
Admetsys Corporation , a biomedical technology company specializing in critical care automation, announced today that it received European regulatory approval (CE Mark) for its flagship PrecisionOne™ automated glycemic control and continuous diagnostics system. The PrecisionOne system functions as a metabolic autopilot, providing autom
-
T1D Exchange Invests In Breakthrough Startup Admetsys To Improve Diabetes Care During Hospitalization
6/6/2017